ClinicalTrials.gg
CompletedNCT00687323TALLUpdated Jun 7, 2017Results posted

Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052)

A Phase 2 interventional study of temozolomide in Leukemia, Acute Myeloid and Myelodysplastic Syndrome, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-07.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jul 2007, registered May 2008).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
47
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Leukemia, Myeloid, Acute by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Leukemia, Myeloid, Acute · Merck & Co., Inc.

Enrollment
5th of 12
47 · median 37
Started
2007
with 1 other
Phase 2
2 of 12
none open now
Registered
2nd of 12
by date

Among the 12 studies in Leukemia, Myeloid, Acute by Merck & Co., Inc, this one is the 5th largest by enrollment, is one of 2 that started in 2007, is one of 2 in phase 2, and was the 2nd registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

None of the 12 studies in Leukemia, Myeloid, Acute by Merck & Co., Inc is open now. The open studies under Leukemia, Myeloid, Acute, anywhere →

Where they have run

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Leukemia, Myeloid, Acute by Merck & Co., Inc as a file.
02

Study summary

The primary objective of this study is to evaluate the safety, tolerability, and efficacy of temozolomide in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) participants who are not candidates for standard induction therapy and exhibit low MGMT expression.

03

Conditions studied

  • Leukemia, Acute Myeloid
  • Myelodysplastic Syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of acute myeloid leukemia (AML), any subtype except acute promyelocytic leukemia (APL), by the World Health Organization (WHO) criteria, or high risk MDS with blasts between 10 and 20% in the bone marrow.
  • No prior AML chemotherapy except hydroxyurea.
  • Leukemic blast count \<30x10\^9/L at the start of therapy. Prior cytoreduction with hydroxyurea (maximum 14 days) is permitted.
  • Participant is not a candidate for aggressive induction based on at least one of the following: adverse-risk cytogenetics (complete or partial deletion of 5 or 7, complex [>3] cytogenetic abnormalities, inv3, 11q23 abnormalities); secondary AML (antecedent hematologic disorder or therapy-related AML); comorbid medical illnesses precluding standard induction therapy; participant's refusal of standard induction therapy.
  • Confirmed low MGMT expression (MGMT: beta-actin ≤0.2), as evaluated by Western blot, or weak MGMT expression defined as > 0.2 and ≤2.5 if promoter is methylated, upon Sponsor approval.
  • (ECOG) performance status of 0, 1, or 2.
  • Use of medically approved in fertile males and females.
  • Negative urine or serum pregnancy test for women of (72 hours prior to Baseline).

Exclusion criteria

Exclusion Criteria:

  • Serum >2 times the (ULN), or serum / alanine aminotransferase >5 times ULN.
  • Serum creatinine >200 umol/L.
  • History of other within 1 year prior to study entry, with the exception of localized nonmelanomatous skin cancer or cervical cancer in situ.
  • Presence of active uncontrolled infection.
  • Known (HIV) infection.
  • Any medical condition that may interfere with protocol evaluation or oral medication intake.
  • Prior chemotherapy other than hydroxyurea.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Temozolomide

    Temozolomide capsules orally, once daily: 1 induction cycle (200 mg/m\^2/day for 7 days in 1 28 day cycle), 1 consolidation cycle (200 mg/m\^2/day for 7 days in 1 28 day cycle), then 200 mg/m\^2/day for 7 days each 28-day cycle or for 5 days each 28-day cycle (12 cycle maximum). Alternatively participants could have received 100 mg/m\^2/day for 21 days of each 28-day cycle (12 cycle maximum).

    Drug: temozolomide

Interventions

06

What researchers measure

Primary outcomes

  1. Clinical Response at the End of Temozolomide Induction

    Complete Response (CR): \< 5% blasts in normocellular bone marrow (BM); Absolute Neutrophil Count (ANC) \> 1.0 x 10\^9/L, platelets \> 100 x 10\^9/L, and no extramedullary disease. CR with incomplete platelet recovery (CRp): All the criteria of CR but with platelets \< 100 x 10\^9/L but ≥ 50 x 10\^9/L and platelet transfusion independent. Morphologic leukemia-free state (MLFS): complete clearance of blasts from marrow and blood, but criteria for CR or CRp not met. Partial response (PR): decrease ≥ 50% BM blasts. Minimal Response (MR): decrease ≥ 25% but \<50% BM blasts.

    Time frame: at the end of each cycle (approximately 4 weeks post start of cycle), up to a maximum 63 weeks

Secondary outcomes

  1. Duration of Response in Participants Achieving Complete Response (CR) and Proceeding to Reduced Dose-intensity Maintenance Therapy With Temozolomide

    Complete Response (CR): \< 5% blasts in normocellular bone marrow (BM); Absolute Neutrophil Count (ANC) \> 1.0 x 10\^9/L, platelets \> 100 x 10\^9/L, and no extramedullary disease.

    Time frame: Up to 1 year after treatment ends (up to 115 weeks)

  2. Relapse-free Survival in Participants Achieving CR or CRp and Proceeding to Reduced Dose-intensity Maintenance Therapy With Temozolomide

    Relapse-free survival was defined as time to disease progression. Complete Response (CR): \< 5% blasts in normocellular bone marrow (BM); Absolute Neutrophil Count (ANC) \> 1.0 x 10\^9/L, platelets \> 100 x 10\^9/L, and no extramedullary disease. CR with incomplete platelet recovery (CRp): All the criteria of CR but with platelets \< 100 x 10\^9/L but ≥ 50 x 10\^9/L and platelet transfusion independent.

    Time frame: Start of treatment until disease progression [up to 1 year after treatment ends (up to 115 weeks)]

  3. Overall Survival (OS) in Participants Achieving CR or CRp and Proceeding to Reduced Dose-intensity Maintenance Therapy With Temozolomide

    OS was defined as the time from start of treatment until death or end of study. Complete Response (CR): \< 5% blasts in normocellular bone marrow (BM); Absolute Neutrophil Count (ANC) \> 1.0 x 10\^9/L, platelets \> 100 x 10\^9/L, and no extramedullary disease. CR with incomplete platelet recovery (CRp): All the criteria of CR but with platelets \< 100 x 10\^9/L but ≥ 50 x 10\^9/L and platelet transfusion independent.

    Time frame: Start of treatment until death or end of study [up to 1 year after treatment ends (up to 115 weeks)]

  4. Number of Previously Untreated Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression

    Low MGMT expression was defined as MGMT/β-actin ratio \< 0.2. MGMT \& β-actin are cancer biomarkers.

    Time frame: Baseline

  5. MGMT Expression in Leukemic Blasts at the Time of Relapse

    Low MGMT expression was defined as MGMT/β-actin ratio of \<0.2. MGMT \& β-actin are cancer biomarkers.

    Time frame: Up to 1 year after treatment ends (up to 115 weeks)

  6. Number of Participants With CR, PR, or MLFS Who Received Modified Low Dose Maintenance Therapy (100 mg/m^2/Day x21 Days of Each 28 Day Cycle) and Experienced Toxicity

    Toxicity was defined as any adverse event experienced by a participant regardless of causal relationship with study treatment. An adverse event (AE) was defined as any untoward medical occurrence in a participant administered a pharmaceutical product, biologic (at any dose), or medical device, which did not necessarily have a causal relationship with the treatment. Adverse events may have included the onset of new illness and/or the exacerbation of preexisting conditions.

    Time frame: From first dose to 30 days after last dose of study drug (up to 67 weeks)

  7. Progression-free Survival for Participants Achieving PR, MLSF, or MR

    Progression-free survival was defined as time to disease progression. Morphologic leukemia-free state (MLFS): complete clearance of blasts from marrow and blood, but criteria for CR or CRp not met. Partial response (PR): decrease ≥ 50% BM blasts. Minimal Response (MR): decrease ≥ 25% but \<50% BM blasts.

    Time frame: Start of treatment until disease progression [up to 1 year after treatment ends (up to 115 weeks)]

  8. Quality of Life (QoL) in Participants Receiving Long Term Temozolomide Therapy Assessed by European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-30

    The EORTC QLQ-C30 was a 30-item questionnaire developed to assess the QoL of cancer patients. Scores ranged from 0 -100. For functional and global QoL scales, higher scores meant a better level of function. For symptom-oriented scales, a higher score meant more severe symptoms and a decrease in QoL.

    Time frame: Baseline and post-study visit (63 weeks)

  9. Quality of Life (QoL) in Participants Receiving Long Term Temozolomide Therapy Assessed by EORTC QLQ-LC13

    The EORTC QLQ-LC13 was a 13-item questionnaire developed to supplement the EORTC QLQ-C30 in lung cancer patients. It had a score range 0-100 with higher scores representing an increase in symptoms.

    Time frame: Baseline and post-study visit (63 weeks)

  10. Quality of Life (QoL) in Participants Receiving Long Term Temozolomide Therapy Assessed by Functional Assessment of Cancer Therapy (FACT)-G

    The FACT-G was a 27-item questionnaire developed to assess the QoL in patients with chronic illnesses. Scores ranged from 0 to 28. For physical well being, lower scores indicated a better outcome. For functional well being, higher scores indicated a better outcome. For social \& emotional well being, whether a high score or a lower one indicated a better outcome depended on the question.

    Time frame: Baseline and post-study visit (63 weeks)

07

Results

Posted Jul 18, 2012

Participant flow

Participant flow — Overall Study
MilestoneTemozolomide
Started195
Received treatment47
Completed15
Not completed180
Withdrew: Death25
Withdrew: Withdrawal by subject1
Withdrew: Excluded from efficacy evaluations6
Withdrew: Screen failure148

Outcome measures

PrimaryClinical Response at the End of Temozolomide Induction

Complete Response (CR): \< 5% blasts in normocellular bone marrow (BM); Absolute Neutrophil Count (ANC) \> 1.0 x 10\^9/L, platelets \> 100 x 10\^9/L, and no extramedullary disease. CR with incomplete platelet recovery (CRp): All the criteria of CR but with platelets \< 100 x 10\^9/L but ≥ 50 x 10\^9/L and platelet transfusion independent. Morphologic leukemia-free state (MLFS): complete clearance of blasts from marrow and blood, but criteria for CR or CRp not met. Partial response (PR): decrease ≥ 50% BM blasts. Minimal Response (MR): decrease ≥ 25% but \<50% BM blasts.

Time frame:
at the end of each cycle (approximately 4 weeks post start of cycle), up to a maximum 63 weeks
Reported as:
Number · participants
Clinical Response at the End of Temozolomide Induction
participantsTemozolomide
CR10
CRp2
MLFS4
PR8
MR7
SecondaryDuration of Response in Participants Achieving Complete Response (CR) and Proceeding to Reduced Dose-intensity Maintenance Therapy With Temozolomide

Complete Response (CR): \< 5% blasts in normocellular bone marrow (BM); Absolute Neutrophil Count (ANC) \> 1.0 x 10\^9/L, platelets \> 100 x 10\^9/L, and no extramedullary disease.

Time frame:
Up to 1 year after treatment ends (up to 115 weeks)
Reported as:
Median · Days
Duration of Response in Participants Achieving Complete Response (CR) and Proceeding to Reduced Dose-intensity Maintenance Therapy With Temozolomide
DaysTemozolomide
Duration of Response in Participants Achieving Complete Response (CR) and Proceeding to Reduced Dose-intensity Maintenance Therapy With Temozolomide408 (101 to 946)
SecondaryRelapse-free Survival in Participants Achieving CR or CRp and Proceeding to Reduced Dose-intensity Maintenance Therapy With Temozolomide

Relapse-free survival was defined as time to disease progression. Complete Response (CR): \< 5% blasts in normocellular bone marrow (BM); Absolute Neutrophil Count (ANC) \> 1.0 x 10\^9/L, platelets \> 100 x 10\^9/L, and no extramedullary disease. CR with incomplete platelet recovery (CRp): All the criteria of CR but with platelets \< 100 x 10\^9/L but ≥ 50 x 10\^9/L and platelet transfusion independent.

Time frame:
Start of treatment until disease progression [up to 1 year after treatment ends (up to 115 weeks)]
Reported as:
Median · months
Relapse-free Survival in Participants Achieving CR or CRp and Proceeding to Reduced Dose-intensity Maintenance Therapy With Temozolomide
monthsTemozolomide
Relapse-free Survival in Participants Achieving CR or CRp and Proceeding to Reduced Dose-intensity Maintenance Therapy With Temozolomide10.5 (4.2 to 19.5)
SecondaryOverall Survival (OS) in Participants Achieving CR or CRp and Proceeding to Reduced Dose-intensity Maintenance Therapy With Temozolomide

OS was defined as the time from start of treatment until death or end of study. Complete Response (CR): \< 5% blasts in normocellular bone marrow (BM); Absolute Neutrophil Count (ANC) \> 1.0 x 10\^9/L, platelets \> 100 x 10\^9/L, and no extramedullary disease. CR with incomplete platelet recovery (CRp): All the criteria of CR but with platelets \< 100 x 10\^9/L but ≥ 50 x 10\^9/L and platelet transfusion independent.

Time frame:
Start of treatment until death or end of study [up to 1 year after treatment ends (up to 115 weeks)]
Reported as:
Median · months
Overall Survival (OS) in Participants Achieving CR or CRp and Proceeding to Reduced Dose-intensity Maintenance Therapy With Temozolomide
monthsTemozolomide
Overall Survival (OS) in Participants Achieving CR or CRp and Proceeding to Reduced Dose-intensity Maintenance Therapy With Temozolomide21.4 (9.7 to NA)
SecondaryNumber of Previously Untreated Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression

Low MGMT expression was defined as MGMT/β-actin ratio \< 0.2. MGMT \& β-actin are cancer biomarkers.

Time frame:
Baseline
Reported as:
Number · participants
Number of Previously Untreated Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression
participantsTemozolomide
Number of Previously Untreated Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression81
SecondaryMGMT Expression in Leukemic Blasts at the Time of Relapse

Low MGMT expression was defined as MGMT/β-actin ratio of \<0.2. MGMT \& β-actin are cancer biomarkers.

Time frame:
Up to 1 year after treatment ends (up to 115 weeks)

No measurements were reported for this outcome.

SecondaryNumber of Participants With CR, PR, or MLFS Who Received Modified Low Dose Maintenance Therapy (100 mg/m^2/Day x21 Days of Each 28 Day Cycle) and Experienced Toxicity

Toxicity was defined as any adverse event experienced by a participant regardless of causal relationship with study treatment. An adverse event (AE) was defined as any untoward medical occurrence in a participant administered a pharmaceutical product, biologic (at any dose), or medical device, which did not necessarily have a causal relationship with the treatment. Adverse events may have included the onset of new illness and/or the exacerbation of preexisting conditions.

Time frame:
From first dose to 30 days after last dose of study drug (up to 67 weeks)
Reported as:
Number · participants
Number of Participants With CR, PR, or MLFS Who Received Modified Low Dose Maintenance Therapy (100 mg/m^2/Day x21 Days of Each 28 Day Cycle) and Experienced Toxicity
participantsTemozolomide
Number of Participants With CR, PR, or MLFS Who Received Modified Low Dose Maintenance Therapy (100 mg/m^2/Day x21 Days of Each 28 Day Cycle) and Experienced Toxicity1
SecondaryProgression-free Survival for Participants Achieving PR, MLSF, or MR

Progression-free survival was defined as time to disease progression. Morphologic leukemia-free state (MLFS): complete clearance of blasts from marrow and blood, but criteria for CR or CRp not met. Partial response (PR): decrease ≥ 50% BM blasts. Minimal Response (MR): decrease ≥ 25% but \<50% BM blasts.

Time frame:
Start of treatment until disease progression [up to 1 year after treatment ends (up to 115 weeks)]
Reported as:
Median · months
Progression-free Survival for Participants Achieving PR, MLSF, or MR
monthsTemozolomide
Progression-free Survival for Participants Achieving PR, MLSF, or MR1.6 (0.3 to 5.8)
SecondaryQuality of Life (QoL) in Participants Receiving Long Term Temozolomide Therapy Assessed by European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-30

The EORTC QLQ-C30 was a 30-item questionnaire developed to assess the QoL of cancer patients. Scores ranged from 0 -100. For functional and global QoL scales, higher scores meant a better level of function. For symptom-oriented scales, a higher score meant more severe symptoms and a decrease in QoL.

Time frame:
Baseline and post-study visit (63 weeks)

No measurements were reported for this outcome.

SecondaryQuality of Life (QoL) in Participants Receiving Long Term Temozolomide Therapy Assessed by EORTC QLQ-LC13

The EORTC QLQ-LC13 was a 13-item questionnaire developed to supplement the EORTC QLQ-C30 in lung cancer patients. It had a score range 0-100 with higher scores representing an increase in symptoms.

Time frame:
Baseline and post-study visit (63 weeks)

No measurements were reported for this outcome.

SecondaryQuality of Life (QoL) in Participants Receiving Long Term Temozolomide Therapy Assessed by Functional Assessment of Cancer Therapy (FACT)-G

The FACT-G was a 27-item questionnaire developed to assess the QoL in patients with chronic illnesses. Scores ranged from 0 to 28. For physical well being, lower scores indicated a better outcome. For functional well being, higher scores indicated a better outcome. For social \& emotional well being, whether a high score or a lower one indicated a better outcome depended on the question.

Time frame:
Baseline and post-study visit (63 weeks)

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TEMOZOLOMIDE—25/47 (53.2%)45/47 (95.7%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventTEMOZOLOMIDE
PNEUMONIAInfections and infestations7/47
FEBRILE NEUTROPENIABlood and lymphatic system disorders5/47
DYSPNOEARespiratory, thoracic and mediastinal disorders4/47
DIARRHOEAGastrointestinal disorders3/47
SEPSISInfections and infestations3/47
MELAENAGastrointestinal disorders2/47
NAUSEAGastrointestinal disorders2/47
ASTHENIAGeneral disorders2/47
FATIGUEGeneral disorders2/47
GENERAL PHYSICAL HEALTH DETERIORATIONGeneral disorders2/47
Most frequent other events
Showing 10 of 47
Most frequent other events
EventTEMOZOLOMIDE
FATIGUEGeneral disorders26/47
DECREASED APPETITEMetabolism and nutrition disorders19/47
CONSTIPATIONGastrointestinal disorders16/47
NAUSEAGastrointestinal disorders14/47
PYREXIAGeneral disorders10/47
DYSPNOEARespiratory, thoracic and mediastinal disorders10/47
PETECHIAESkin and subcutaneous tissue disorders10/47
VOMITINGGastrointestinal disorders9/47
FEBRILE NEUTROPENIABlood and lymphatic system disorders8/47
HYPOKALAEMIAMetabolism and nutrition disorders8/47

Baseline characteristics

Age, Continuous
Age, Continuous(years)Temozolomide
Mean75 (52 to 89)
Sex: Female, Male
Sex: Female, Male(Participants)Temozolomide
Female18
Male29
Region of Enrollment
Region of Enrollment(participants)Temozolomide
Canada47
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Brandwein JM, Yang L, Schimmer AD, Schuh AC, Gupta V, Wells RA, Alibhai SM, Xu W, Minden MD. A phase II study of temozolomide therapy for poor-risk patients aged >or=60 years with acute myeloid leukemia: low levels of MGMT predict for response. Leukemia. 2007 Apr;21(4):821-4. doi: 10.1038/sj.leu.2404545. Epub 2007 Jan 25. No abstract available. PubMed 17252015 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2007 to primary completion in May 2011, 45 months.

Results were first posted in Jul 2012, 1 year 2 months after primary completion.

Of 57 industry-sponsored phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 55. This study's 45 months is above that.

Counting every sponsor, half of 443 studies reached it within 60 months; a quarter within 38 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2008
First posted
May 30, 2008
StartActual
Jul 30, 2007
Primary completionActual
May 9, 2011
CompletionActual
Dec 23, 2012
Results first posted
Jul 18, 2012
Last update
Jun 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00687323
Responsible party
Sponsor
First posted
May 30, 2008
Start date
Jul 30, 2007
Primary completion
May 9, 2011
Completion
Dec 23, 2012
Results posted
Jul 18, 2012
Last update
Jun 7, 2017

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Temozolomide

Start the discussion